Stereotaxis Stock

Stereotaxis Equity

The The Equity of Stereotaxis (STXS) as of Aug 19, 2026 is 18.72 M USD. In the previous year, The Equity was 11.43 M USD — a change of 63.76% (higher).

Equity

18.72 MUSD

YoY

63.76%

Last updated:

In 2026, Stereotaxis's equity was 18.72 M USD, a 63.76% increase from the 11.43 M USD equity in the previous year.

Access this data via the Eulerpool API

Stereotaxis Stock analysis

What does Stereotaxis do? Stereotaxis Inc, based in St. Louis, Missouri, is a company that specializes in the development and marketing of advanced instruments and services in magnetic resonance imaging (MRI) and electrophysiology (EP). The company was founded in 1990 and its mission is to improve the accuracy, safety, and efficiency of MRI and EP procedures. The business model of Stereotaxis is based on providing a comprehensive range of systems, instruments, and services to support hospitals and clinics in performing MRI and EP procedures. The company focuses on developing innovative technologies and solutions to improve clinical outcomes and provide the best possible treatment for patients. The company has four main divisions: magnetic resonance imaging (MRI), electrophysiology (EP), cardiovascular diagnostics, and cardiology. In the MRI division, the company offers a variety of instruments and systems specifically designed for MRI procedures. This includes magnetic field control systems, imaging systems, sample collection and analysis instruments, and controls to make MRI procedures more efficient. In the electrophysiology division, Stereotaxis offers instruments and systems that facilitate the navigation and control of medical devices during EP procedures. This includes magnetic field controls and other technologies to improve the accuracy of catheter placement and increase safety during procedures. Stereotaxis's cardiovascular diagnostics division offers various services and technologies that facilitate the performance of cardiology procedures. This includes a comprehensive diagnostic platform that allows for the analysis of heart images. The cardiology division of Stereotaxis offers a comprehensive range of solutions to improve the performance of cardiology procedures in cardiology clinics and hospitals. This includes a range of technologies to improve the diagnosis and treatment of heart diseases. In recent years, Stereotaxis has developed a variety of innovative solutions and technologies to improve the performance of MRI and EP procedures. One example is Robotic Magnetic Navigation, a technology developed by the company to improve the accuracy and safety of EP procedures. This technology allows doctors to improve the navigation and control of catheters during procedures, thereby providing patients with increased treatment safety. Another example is Stereotaxis's Odyssey platform, a solution developed to enable real-time connectivity between various medical devices. This allows doctors to access a variety of information during procedures and make the performance of procedures more efficient. Overall, Stereotaxis has an impressive track record in the development and marketing of advanced solutions and technologies in the MRI and EP industry in recent years. With its innovative technology and comprehensive range of instruments and services, the company is well positioned to continue playing a key role in healthcare in the future. Stereotaxis is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Stereotaxis's Equity

Stereotaxis's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Stereotaxis's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Stereotaxis's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Stereotaxis's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Stereotaxis’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Stereotaxis stock

The Equity of Stereotaxis is 18.72 M USD in 2026.

The Equity of Stereotaxis changed from 11.43 M USD to 18.72 M USD, representing a 63.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Stereotaxis since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Stereotaxis historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Stereotaxis

All Key Metrics — Stereotaxis